Image
Mary Rozenman
Chief Finance Officer, Chief Business Officer, insitro
Mary Rozenman, Ph.D. CFO|CBO insitro Dr. Mary Rozenman is Chief Financial Officer and Chief Business Officer of insitro, the physical AI company built on causal human biology that is transforming how new medicines are made. Since 2019, she has led insitro’s strategic and operational functions, including finance and accounting, business development, investor relations and corporate communications. Prior to insitro, Dr. Rozenman was Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she was a founding team member, co‑led the company’s 2015 IPO, and collaborations leading to its $2.6 billion acquisition by Nestlé Health Sciences. Earlier, she was a biotechnology investor at Longitude Capital and an associate principal at McKinsey & Company, advising clients in pharmaceuticals and corporate finance.
Dr. Rozenman serves as an independent director on the board of Tessera Therapeutics, a company pioneering gene‑writing technologies, and has been recognized by Endpoints News and Business Insider among the biopharma industry’s emerging leaders.
She earned a Ph.D. in Organic Chemistry and Chemical Biology from Harvard University, where she worked with David R. Liu, and a B.A. from Columbia University, where she was a John Jay Scholar.